30 July 2013

US court rules Teva patent invalid

A US court has ruled that an Israeli company’s patent for a multiple sclerosis (MS) drug is invalid, paving the way for rivals to market a generic version.

In a ruling at the US Court of Appeals for the Federal Circuit on Friday, July 26, Teva Pharmaceuticals was told one of its patents protecting the Copaxone drug was invalid. The patent in question was due to expire in 2015; other patents at issue were upheld by the court, but these expire in 2014.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Pharma

USPTO director steps into Sun Pharma’s PTAB-ITC clash

31 July 2026 A director review has overturned a PTAB ruling, questioning why it diverged from an ITC decision based on the same patent claims, prior art and evidence.

Careers

USPTO appoints new acting commissioner for patents

31 July 2026 The ex-Greenberg Traurig shareholder will oversee the office’s 14,000-strong patent division, as the agency prepares for the departure of deputy director Coke Morgan Stewart.

MedTech

European court strikes down hearing aid sensor patent

30 July 2026 A dispute over optical sensor technology in miniature hearing devices ended with the EPO revoking a patent, finding the invention obvious despite ruling it was new over the closest prior art.